These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1092101)

  • 1. [Antibodies to erythrogenic toxin B in scarlatina patients].
    Silich VA; Fiks LI; Dodonov VN; Sezonova EP
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Mar; 0(3):112-5. PubMed ID: 1092101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The passive hemagglutination test for detection of antibodies to scarlet fever toxin].
    Silich VA; Fiks LI; Cherkasskaia RS
    Zh Mikrobiol Epidemiol Immunobiol; 1972 Aug; 49(8):57-62. PubMed ID: 4673601
    [No Abstract]   [Full Text] [Related]  

  • 3. [Characteristics of antitoxic immunity in patients with scarlatina according to passive hemagglutination reaction data].
    Silich VA; Fiks LI; Dodonov VN; Sezonova EP; Novik ZA
    Zh Mikrobiol Epidemiol Immunobiol; 1973 Jul; 50(7):19-23. PubMed ID: 4590982
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mitogenic activity of erythrogenic toxins. I. Type-specific inhibition of the mitogenic activity of erythrogenic toxins by antitoxic antisera from the rabbit (author's transl)].
    Petermann F; Knöll H; Köhler W
    Zentralbl Bakteriol Orig A; 1978 Apr; 240(3):366-79. PubMed ID: 352038
    [No Abstract]   [Full Text] [Related]  

  • 5. [Erythrogenic toxin. II. The problem of antigenic heterogeneity of scarlet fever toxin. Neutralization tests].
    SCHUH V; JELINEK J
    Cesk Epidemiol Mikrobiol Imunol; 1960 Sep; 9():476-84. PubMed ID: 13748788
    [No Abstract]   [Full Text] [Related]  

  • 6. [A comparative experimental study of 3 depot preparations of scarlet fever erythrogenic toxin].
    KUSHKO IV; AKIMOVA VV
    Zh Mikrobiol Epidemiol Immunobiol; 1960 Aug; 31():51-4. PubMed ID: 13755376
    [No Abstract]   [Full Text] [Related]  

  • 7. [Type specific antistreptococcal antibodies in the passive hemagglutination test].
    Silich VA; Fiks LI; Sokolova MS; Orlova EV; Cherkasskaia RS
    Zh Mikrobiol Epidemiol Immunobiol; 1976 Apr; (3):40-4. PubMed ID: 785907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Virulent and toxigenic properties of beta-hemolytic streptococci in relation to the scarlatina epidemic process].
    Gladkova KK; Dodonov VN; Bliumental' KV; Cherkasskaia RS; Severov AM
    Zh Mikrobiol Epidemiol Immunobiol; 1973 Jul; 50(7):24-7. PubMed ID: 4272990
    [No Abstract]   [Full Text] [Related]  

  • 9. [A method for the quantitative estimation of antibodies to extracellular esterases produced by group A and B streptococci, and application to the sera of patients with scarlet fever (author's transl)].
    Hayano S; Tanaka A
    Kansenshogaku Zasshi; 1981 May; 55(5):339-45. PubMed ID: 6798138
    [No Abstract]   [Full Text] [Related]  

  • 10. Streptococcal superantigens and the return of scarlet fever.
    Hurst JR; Brouwer S; Walker MJ; McCormick JK
    PLoS Pathog; 2021 Dec; 17(12):e1010097. PubMed ID: 34969060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the immunological and epidemiological activity of purified sorbed scarlet fever toxin].
    MITEL'MAN SL
    Zh Mikrobiol Epidemiol Immunobiol; 1960 Aug; 31():70-5. PubMed ID: 13771373
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antigenic composition of preparations of purified erythrogenic toxin].
    Kazdobina IS; Akimova VV; Burshteĭn VA
    Zh Mikrobiol Epidemiol Immunobiol; 1966 May; 43(5):111-6. PubMed ID: 4975809
    [No Abstract]   [Full Text] [Related]  

  • 13. [Determination of antibodies to erythrogenic toxin in the passive hemagglutination reaction].
    Kazdobina IS
    Zh Mikrobiol Epidemiol Immunobiol; 1967; 44(3):43-7. PubMed ID: 5616806
    [No Abstract]   [Full Text] [Related]  

  • 14. Stimulation of human T cells by streptococcal "superantigen" erythrogenic toxins (scarlet fever toxins).
    Braun MA; Gerlach D; Hartwig UF; Ozegowski JH; Romagné F; Carrel S; Köhler W; Fleischer B
    J Immunol; 1993 Mar; 150(6):2457-66. PubMed ID: 8450222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of serum antibody by the antimitogen assay against streptococcal erythrogenic toxins. Age distribution in children and the relation to Kawasaki disease.
    Abe Y; Nakano S; Nakahara T; Kamezawa Y; Kato I; Ushijima H; Yoshino K; Ito S; Noma S; Okitsu S
    Pediatr Res; 1990 Jan; 27(1):11-5. PubMed ID: 2404253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between anti-streptokinase levels and hemolytic streptococcal types in scarlet fever].
    Shimizu H; Iimura T; Yagishita N; Nagase K
    Kansenshogaku Zasshi; 1973 Dec; 47(12):522-3. PubMed ID: 4208601
    [No Abstract]   [Full Text] [Related]  

  • 17. [Toxigenic hemolytic streptococci isolated from patients with scarlatina and those having contact with them].
    Cherkasskaia RS; Dodonov VN; Silich VA; Gladkova KK; Fiks LI
    Zh Mikrobiol Epidemiol Immunobiol; 1973 Jan; 50(1):67-72. PubMed ID: 4273361
    [No Abstract]   [Full Text] [Related]  

  • 18. Reactions to intradermal administration of scarlet fever streptococcus toxin in rheumatic cardiac children.
    DOWD HL; WASSON VP; BROWN EE
    Arch Pediatr (N Y); 1945 Dec; 62():549-53. PubMed ID: 21010702
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-streptopolysaccharide antibody in children with rheumatic fever and scarlet fever.
    Watanabe N; Mikuni K; Nakamura Y
    Jpn Circ J; 1987 Dec; 51(12):1350-2. PubMed ID: 3327951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serological study on scarlet fever].
    Nakamizo Y; Tsuji S; Shimizu H
    Kansenshogaku Zasshi; 1973 Dec; 47(12):519-21. PubMed ID: 4208600
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.